Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ACHE | P22303 | 1/20 | 0.56 |
| ▸ | PBRM1 | Q86U86 | 1/20 | 0.55 |
| ▸ | NPC1 | O15118 | 1/20 | 0.47 |
| ▸ | MITF | O75030 | 1/20 | 0.47 |
| ▸ | LMNA | P02545 | 1/20 | 0.47 |
| ▸ | POLB | P06746 | 1/20 | 0.47 |
| ▸ | F2 | P00734 | 1/20 | 0.47 |
| ▸ | PLG | P00747 | 1/20 | 0.47 |
| ▸ | PRSS1 | P07477 | 1/20 | 0.47 |
| ▸ | PRSS2 | P07478 | 1/20 | 0.47 |
| ▸ | PRSS3 | P35030 | 1/20 | 0.47 |
| ▸ | KDM4C | Q9H3R0 | 1/20 | 0.46 |
| ▸ | PTGS1 | P23219 | 2/20 | 0.44 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.44 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.44 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.44 |
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.42 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.42 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.42 |
| ▸ | CASP1 | P29466 | 1/20 | 0.42 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL5091376 | 0.81 | PBRM1 (0.65) | PBRM1NPC1MITFLMNAPOLB | |
| SCHEMBL9254112 | 0.80 | PBRM1 (0.55) | PBRM1NPC1MITFLMNAPOLB | |
| SCHEMBL9041395 | 0.78 | PBRM1 (0.53) | PBRM1NPC1MITFLMNAPOLB | |
| SCHEMBL8344640 | 0.77 | PBRM1 (0.61) | PBRM1NPC1MITFLMNAPOLB | |
| SCHEMBL9282073 | 0.76 | PBRM1 (0.87) | PBRM1NPC1MITFLMNAPOLB | |
| SCHEMBL125621 | 0.76 | PBRM1 (0.87) | PBRM1NPC1MITFLMNAPOLB | |
| SCHEMBL29363032 | 0.76 | PBRM1 (0.87) | PBRM1NPC1MITFLMNAPOLB | |
| SCHEMBL362529 | 0.76 | PARP1 (0.57) | ACHENPC1SMN1; SMN2NPSR1ALDH1A1 | |
| SCHEMBL9560384 | 0.76 | PBRM1 (0.50) | PBRM1NPC1MITFLMNAPOLB | |
| SCHEMBL9732241 | 0.76 | L3MBTL1 (0.66) | PBRM1NPC1MITFLMNAPOLB |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20220324835-A1 | INHIBITORS OF CBL-B AND METHODS OF USE THEREOF | NURIX THERAPEUTICS, INC. | 2022-10-13 | — | — | US | disclosed |
| EP-3743063-A1 | INHIBITORS OF CBL-B AND METHODS OF USE THEREOF | Nurix Therapeutics, Inc. (US) | 2020-12-02 | — | — | EP | disclosed |
| WO-2019148005-A1 | INHIBITORS OF CBL-B AND METHODS OF USE THEREOF | NURIX THERAPEUTICS, INC. (US) | 2019-08-01 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20220324835-A1 | INHIBITORS OF CBL-B AND METHODS OF USE THEREOF | CBLB, CBL, CBLC | ACHE 3106/4885PBRM1 1503/4885NPC1 2741/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.